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Abstract: Background: The role of liver kinase B1 (LKB1), a serine/threonine kinase, has been
described in the development of PeutzJagher’s syndrome, where a proportion (~45%) of patients
have developed breast cancer in their lifetime. Cell line studies have linked LKB1 with oestrogen
receptors (ER) and with the Adenosine monophosphate-activated protein kinase (AMPK) pathway
for energy metabolism. However, limited studies have investigated protein expression of LKB1 in
tumour tissues and its intracellular relationships. This study aimed to investigate the intracellular
molecular relationships of LKB1 in older women with early operable primary breast cancer and
its correlation with long-term clinical outcome. Methods: Between 1973 and 2010, a consecutive
series of 1758 older (≥70 years) women with T0-2N0-1M0 breast carcinoma were managed in a
dedicated facility. Of these, 813 patients underwent primary surgery, and 575 had good quality
tumour samples available for tissue microarray construction. LKB1 was assessed in 407 cases by
indirect immunohistochemistry (IHC). Tumours with 30% or more of cells with cytoplasmic LKB1
expression were considered positive. LKB1 expression was compared with tumour size, histological
grade, axillary lymph node stage, ER, PgR, EGFR, HER2, HER3, HER4, BRCA1&2, p53, Ki67, Bcl2,
Muc1, E-Cadherin, CD44, basal (CK5, CK5/6, CK14 and CK17) and luminal (CK7/8, CK18 and CK19)
cytokeratins, MDM2 and MDM4, and correlated with long-term clinical outcome. Results: Positive
LKB1 expression was seen in 318 (78.1%) patients, and was significantly associated with high tumour
grade, high Ki67, over-expression of HER2, VEGF, HER4, BRCA2, MDM2 and negative expression
of CD44 (p < 0.05). There was no significant correlation with tumour size, axillary lymph node
status, ER, PgR, p53, basal or luminal cytokeratins, Bcl2, Muc1, EGFR, HER3, MDM4, E-cadherin and
BRCA1. LKB1 did not show any significant influence on survival in the overall population; however,
in those patients receiving adjuvant endocrine therapy for ER positive tumours, those with positive
LKB1 had significantly better 5-year breast cancer specific survival when compared to those without
such expression (93% versus 74%, p = 0.03). Conclusion: LKB1 expression has shown association with
poor prognostic factors in older women with breast cancer. However, LKB1 expression appears to be
associated with better survival outcome among those patients receiving adjuvant endocrine therapy.
Further research is required to explore its potential role as a therapeutic target.
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1. Introduction
Liver kinase B1 (LKB1) or serine/threonine kinase-11, a 436-amino acid chain protein with a
molecular weight of 49 kDa, is associated with the development of Peutz-Jeghers syndrome (PJS) [1,2].
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In addition, approximately 45% of PJS patients have been reported to develop breast cancer in their
lifetime [3]. LKB1 is known to work as a tumour suppressor gene as well as an upstream kinase which
is linked to the cellular functions during normal state and in metabolic stress response [4,5]. LKB1 is
normally located in the nucleus, however, upon activation, it is relocated to the cytoplasm, where it
acts as a co-activator of the oestrogen receptor (ER), controls the citric acid cycle (KREB’s cycle) and
cell energy metabolism via the adenosine mono-phosphate activated protein kinase (AMPK) pathway,
and inhibits the production of the aromatase enzyme [6–11]. It has also been reported to control the
cell cycle at the G0–G1 check point via the p53 pathway, to be associated with angiogenesis through
the control of Vascular Endothelial Growth Factor (VEGF) and with cell polarity [8,11,12]. A proposed
mechanism of LKB1 function in breast cancer cells is presented in Figure 1. Previously, reported
data linked LKB1 with poor prognostic factors [11]. A cell line study on MDA-MB-231 cells showed
an association of LKB1 with gemcitabine resistance [13]. Additionally, cell line studies suggested
that LKB1 is involved in DNA repair, thus deficient cells demonstrate delayed repair and respond
well to DNA-based therapy, such as PARP inhibitors [14]. Cell-based studies showed that LKB1-null
cells possess invasion and breast cancer stem cell like properties. However, LKB1 enhancing therapy
(i.e., Honokoil, a bioactive molecule) showed improving outcome by reducing cellular invasiveness
and stemness [15], thus suggesting a therapeutic significance.
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2. Materials and Methods
2.1. Patients
Over 37 years (1973–2010), 1758 older (≥70 years) women with early operable primary breast
cancer (T0-2, N0-1, M0) were managed in a dedicated facility in a single institution with clinical
information available from diagnosis till death/last follow-up. Eight hundred and thirteen patients
underwent primary surgery (with optimal adjuvant therapy as per unit policy at the time [17]) and
among them, good quality formalin-fixed paraffin-embedded surgical specimens were available from
575 patients for tissue microarray (TMA) construction. The management pattern over this period
of time was evolving, a detailed description of which was reported earlier [17]. Briefly during the
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1970s and 1980s, ER status was not available and there was no consensus on recommendations for
adjuvant systemic therapy. During the 1990s, adjuvant endocrine therapy was advised based on the
clinical judgement of the treating physician and/or the patient’s choice. In the recent decade, there
have been structured recommendations for the use of adjuvant endocrine therapy. Those patients with
ER positive tumours and Nottingham Prognostic Index (NPI) <3 (excellent prognostic group) were not
given any adjuvant systemic therapy, those with an NPI of 3–3.4 (good prognostic group) were offered
endocrine therapy and given the choice of tamoxifen or a non-steroidal aromatase inhibitor, and
those with an NPI of >3.4 (moderate to poor prognostic group) were given a non-steroidal aromatase
inhibitor. Adjuvant chemotherapy was considered in fit, relatively younger patients with moderate to
poor prognostic tumours, in particular those with ER negative tumours. Trastuzumab was considered
in relatively fit patients with HER2 positive tumours having moderate to poor prognosis.
2.2. Tissue Microarray Construction
Tissue microarrays (TMAs) of formalin-fixed paraffin-embedded tumour sections were
constructed as described [18]. Briefly, 0.6 mm-diameter cores of the representative part of the tumour
blocks were implanted in the TMA blocks using Beecher’s manual tissue microarrayer (MP06 Beecher
Instruments Inc, Sun Prairie, WI, USA).
2.3. Immunohistochemistry
LKB1 and 24 other biological markers including ER, progesterone receptor (PgR), Epidermal
Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor (HER)-2, HER3, HER4,
Breast Cancer Associated gene (BRCA)1&2, p53, Ki67, B-Cell Lymphoma (Bcl)2, Mucin (MUC)1,
E-Cadherin, basal (CK5, CK5/6, CK14 and CK17) and luminal (CK7/8, CK18 and CK19) cytokeratins,
and Mouse Double Minute (MDM)2 and MDM4 were analysed using indirect IHC by StreptAvidin
Biotin Complex and EnVision methods as described [19].
2.4. Scoring
Immunohistochemical staining of biological markers was assessed by the percentage of invasive
tumour cells stained and by McCarty’s immunohistochemical scoring (H-score) (range 0–300) [20]. The
LKB1 expression of 30% or more positive cells was considered positive (Figure 2a–d). Previously, studies
have shown that the active form of LKB1 is found in the cytoplasm and is associated with other markers
and outcome of breast cancer; thus, cytoplasmic expression of LKB1 was considered in our study [21].
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. . tatistical Analysis
X-tile bio-infor atics software (Yale University, New Haven, CT, USA) was used to define cut-offs
for positivity of the expression of the biological markers based on breast cancer specific survival
(BCSS) [22]. The cut-offs for all the biological markers were determined by using the same metric
in X-tile. The cut-off values to define positive expression are the same as reported earlier [23]. The
Statistical Package for Social Sciences (SPSS, version 16.0, Chicago, IL, USA) was used for data
collection and analysis. A Chi-squared test was used for the analysis of the association of the LKB1
with other biomarkers in terms of expression. The clinical outcome was evaluated in terms of BCSS,
metastases free survival, local recurrence free survival and regional recurrence free survival, breast
cancer specific survival was defined as survival from the date of diagnosis till death from breast cancer;
metastases free, local recurrence free and regional recurrence free survivals were calculated from the
date of diagnosis till the appearance of the respective recurrences. Survival was analysed by using
Kaplan-Meier methods with application of log-rank and generalised Wilcoxon tests, as appropriate.
A p-value of <0.05 was considered significant.
2.6. Ethical Consideration
The study was approved by the Nottingham Research Ethics Committee 2 under ethical approval
number C2020313.
3. Results
3.1. Patients
Of the 575 patients who had TMAs constructed from surgical specimens, 168 cores were lost
during the IHC process and 407 cases had LKB1 measured. T e median age of the patients was 76
(range 70–91) years, with the majority having had no axillary lymph node i volvement (54.2%). Most
of the patients ( = 296 (72.7%)) underwent a mastectomy and 46.6% of patients (n = 189) received
adjuvant endocri e therapy. None of these patients received chemotherapy. The median follow-up
was 60 months (longest = 261 months).
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3.2. Pattern of LKB1 Expression and Association with Other Clinico-Pathological Parameters and
Biological Markers
Overall, 78.1% (n = 318) of patients showed positive cytoplasmic expression of LKB1 in
their tumours.
3.2.1. Pathological Parameters
The expression of LKB1 was significantly associated with high histological grade (among LKB1
positive, grade 1&2 = 44.5%, grade 3 = 55.5%; among LKB1 negative, grade 1&2 = 59.2% and grade
3 = 40.8%, p = 0.01).However there was no statistically significant correlation with tumour size(among
LKB1 positive, <3 cm = 81.7% and among LKB1 negative, <3 cm = 75.6%, p = 0.15) and axillary lymph
node status (among LKB1 positive:, stage 1&2 = 87.1%, stage 3 = 12.9%, among LKB1 negative, stage
1&2 = 89.5%, stage 3 = 10.5%, p = 0.41).
3.2.2. Biological Markers
The positive expression of LKB1 was significantly associated with positive expression of HER2
(p = 0.003), Ki67 (p = 0.01), VEGF (p = 0.002), HER4 (p = 0.001), BRCA2 (p = 0.01) and MDM2 (p < 0.001),
and negative expression of CD44 (p = 0.03). However, there was no statistically significant correlation
with, ER, PgR, p53, basal or luminal cytokeratins, Bcl2, Muc1, EGFR, HER3, MDM4, E-cadherin, and
BRCA1.A, as summarised in Table 1.
Table 1. Intracellular relationships between LKB1 with biological markers in older women with early
operable primary breast cancer.
Biomarker LKB1 Positive N (%) LKB1 Negative N (%) p-Value
ER + ve 211 (69.0) 61 (72.6) 0.30
PgR + ve 168 (55.1) 52 (61.9) 0.16
HER2 + ve 30 (9.6) 2 (2.4) 0.01
Ki67 + ve 114 (35.8) 20 (22.5) 0.01
MUC1 + ve 274 (89.0) 73 (86.9) 0.36
Bcl2 + ve 250 (83.1) 69 (83.1) 0.56
P53 + ve 123 (41.1) 31 (39.7) 0.46
CK5 + ve 104 (33.7) 21 (24.7) 0.07
CK5/6 + ve 128 (45.2) 33 (42.3) 0.37
CK7/8 + ve 301 (97.4) 84 (98.8) 0.38
CK14 + ve 73 (25.8) 15 (18.5) 0.11
CK17 + ve 70 (23.4) 14 (16.7) 0.11
CK18 + ve 286 (97.3) 81 (96.4) 0.45
CK19 + ve 291 (95.4) 79 (96.3) 0.49
EGFR + ve 65 (23.0) 12 (14.8) 0.07
BRCA2 + ve 160 (56.7) 35 (42.7) 0.01
VEGF + ve 234 (88.6) 56 (73.7) 0.002
CD44 + ve 61 (19.7) 25 (29.8) 0.03
MDM2 + ve 296 (96.7) 60 (74.1) <0.001
E-Cadherin + ve 191 (63.2) 48 (57.1) 0.18
Expression of LKB1 in molecular classes of breast cancer
Luminal A 79 (76.0) 25 (24.0)
0.09
Luminal B 56 (75.7) 18 (24.3)
Low ER Luminal 36 (81.8) 8 (18.2)
All low expression/normal like 13 (76.5) 4 (23.5)
Basal Like 19 (73.1) 7 (26.9)
HER2 positive 25 (96.2) 1 (3.8)
ER: Oestrogen receptor, HER2: Human Epidermal Receptor 2.
Cancers 2019, 11, 149 6 of 17
3.3. Correlation with Molecular Classes of Breast Cancer
The expression of LKB1 was correlated with molecular classes (subtypes) of breast cancer found
in older women (published previously [23]). The results showed no significant difference in the
expression across them (Table 1).
3.4. Association of LKB1 with Clinical Outcome
Breast Cancer Specific Survival (BCSS)
At a median follow-up of 60 months (longest 261 months), LKB1 did not show any significant
association with BCSS (Figure 3a. However, among those who received adjuvant endocrine therapy
(n = 267), patients with ER positive disease and positive LKB1 expression (ER+/LKB1+) showed
significantly better BCSS (5-year: 93%versus 74%, p = 0.03) (Figure 3b). However, in the absence of
adjuvant endocrine therapy, LKB1 did not produce any significant impact on survival (p = 0.85). For
patients with positive LKB1, positive expression of ER (p < 0.001, Figure 4a), PgR (p = 0.001, Figure 4b),
MUC1 (p = 0.003, Figure 4c) and Bcl2 (p < 0.001, Figure 4d) was associated with significantly better
BCSS but poorer BCSS in cases of positive expression of HER2 (p < 0.001, Figure 4e), Ki67 (p = 0.01,
Figure 4f), CK17 (p = 0.02, Figure 4g) and EGFR (p = 0.03, Figure 4h).
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recurrence-free survival and LKB1 expression (p > 0.05). Figure S1a–e). Nevertheless, among patients 
with positive LKB1, positive expression of ER (p < 0.001, Figure 5a), PgR (p = 0.001, Figure 5b), MUC1 
(p = 0.002, Figure 5c), Bcl2 (p = 0.004, Figure 5d) and negative expression of HER2 were associated 
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Figure 4. Breast cancer specific survival in LKB1 positive early operable primary breast cancer in
older women: (a) Oestrogen receptor positive versus oestrogen receptor negative. (b) Progesterone
receptor(PgR) positive versus Progesterone Receptor negative, (c) Mucin (MUC)-1 positive versus
Mucin 1 negative, (d) B-Cell Lymphoma-2 (Bcl2) positive versus B-Cell Lymphoma 2 negative,
(e) Human Epidermal Growth Factor Receptor-2(HER2) positive versus Human Epidermal Growth
Factor Receptor-2 negative, (f) Ki67 positive versus Ki67 negative, (g) Cytokeratin 17(CK17) positive
versus Cytokeratin 17 negative, (h) Epidermal Growth Factor Receptor (EGFR) positive versus
Epidermal Growth Factor Receptor negative.
3.5. Recurrence Free Survival
There was no significant correlation between metastases-, local recurrence- or regional
recurrence-free survival and LKB1 expression (p > 0.05). Figure S1a–e). Nevertheless, among patients
with positive LKB1, positive expression of ER (p < 0.001, Figure 5a), PgR (p = 0.001, Figure 5b), MUC1
(p = 0.002, Figure 5c), Bcl2 (p = 0.004, Figure 5d) and negative expression of HER2 were associated with
better metastases-free survival (p = 0.01, Figure 5e). While Ki67 (Figure S2a), CK17 (Figure S2b) and
EGFR (Figure S2c) did not show any significant influence on metastases free survival.
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Figure 5. (a) Metastasis-free survival in LKB1 positive early operable primary breast cancer in older
women: ER positive versus ER negative. (b) Metastasis-free survival in LKB1 positive early operable
primary breast cancer in older women: PgR positive versus PgR negative. (c) Metastasis-free survival
in LKB1 positive early operable primary breast cancer in older women: MUC1 positive versus MUC1
negative. (d) Metastasis-free survival in LKB1 positive early operable primary breast cancer in older
women: Bcl2 positive versus Bcl2 negative. (e) Metastasis-free survival in LKB1 positive early operable
primary breast cancer in older women: HER2 positive versus HER2 negative.
4. Discussion
Results of the analysis showed that cytosolic expression of LKB1 was associated with high-grade
tumours and positive expression of HER2, Ki67 and VEGF. Within the population with LKB1 positive
tumours, BCSS was significantly better in patients who received adjuvant endocrine therapy.
The expression of LKB1 in tumours cells was previously reported as 71%, which is slightly lower
than the expression reported in our population (78%) [24]. This could be explained by the age of
the population, as our study included patients 70 years or older, while the previously reported data
included four groups with median ages of 48, 54, 61 and 62 years [24]. In our study, the association
between LKB1 positivity and the factors mentioned above suggests its role as a possible poor prognostic
indicator. The association of LKB1 expression with high histological grade suggests a poor prognostic
indication as reported previously, where IHC was used for the detection of LKB1 protein expression [24].
While in vitro studies reported a negative correlation between both LKB1 mutation and grade and
VEGF and a positive correlation with hormone receptor expression [1,3,12,25], these studies analysed
LKB1 using Western blot and RT-PCR [1,3,11]. A recently presented study suggested that the nuclear
location of LKB1 was associated with better survival while cytosolic expression is an indi ator of poor
prognosi [25]. Another study analysed both nuclea nd cytoplasmic expression (n = 32) on IHC in
early op rable primary breast cancer with ER and PgR po itive expressi n [26]. High cytoplasmic
expression as seen in 62.5% of cases, which wa not associated with age, ER, PgR and HER2, but
was shown to be significantly associated with smaller tumour size [26]. In this study, the nuclear
expression was also associated with smaller tumours and better survival. A high LKB1 gene expression
has been reported to be linked to a high ER expression [24]. The expression of LKB1 has shown its
association with CD44, which is a marker of stemness in breast cancer stem cells. Previously, the
available literature showed LKB1 as a factor for maintenance of stem cells in haemopoetic cells in a
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mouse model study, where animals with LKB1 deletion had progressive pancytopenia and reduction
in haemopoetic cell proliferation [27–29]. In this study, LKB1 has also shown its significant association
with VEGF, probably linked to tumour growth and invasion. A recent study has demonstrated the
influence of LKB1 on tumour invasion and metastases in colorectal cancer and suggested it to be a
potential therapeutic marker [30].
The expression of LKB1 among molecular classes or subtypes has not been reported in the
literature. Though it did not show any remarkable findings in our data analyses, its relatively high
expression in the HER2 over-expressing class may be linked to some relationship with growth factor
pathways. As it was previously reported, it may be a potential predictor of overall survival among
HER2 positive breast cancer patients [24].
The prognostic significance of LKB1 was clinically demonstrated in the group of patients who
received adjuvant endocrine therapy. This is an interesting finding, which is in line with the data
previously reported, which suggested that within the stress environment, 17β oestradiol stimulatesthe
AMPK pathway. The same study has also suggested that LKB1 is required for the ER mediated
activation of AMPK [31,32]. The tumour analysis of the patients included in the TAMRAD randomized
GINECO trial (the trial compared tamoxifen versus tamoxifen plus everolimus in ER+ metastatic
breast cancers). It reported that the patients with a low cytoplasmic expression of LKB1 demonstrated
a 67% reduction in the risk of disease progression with everolimus (a mammalian target of rapamycin
(mTOR) inhibitor) plus tamoxifen, when compared to the tamoxifen only arm [33]. On the other hand,
high cytoplasmic expression was associated with less benefit with everolimus therapy, consistent with
our results, suggesting the predictive role of LKB1 in patients with ER positive tumours.
In addition, LKB1 has been previously reported to inhibit the aromatase enzyme via the
AMP-activated protein kinase, thus supporting its potential role in the prediction of the response to
primary endocrine therapy in older women [7,10,26].
The study has limitation of not including the comparison with the younger women and not
studying the gene expression and mutations in older women. Precisely defining an expression cut-off
based on IHC remains a challenge as this could vary between laboratories.
5. Conclusions
The available literature reported on LKB1 are primarily based on in vitro and in vivo studies using
Western blot or PCR techniques. Our work describes a novel study which analysed the relationship
between LKB1 and other biomarkers and clinical outcome in a large series of older patients with
breast cancer by using IHC. Given the availability of IHC in clinical practice, this study possesses
translational significance. The study has demonstrated significant correlations between LKB1 and
biological markers of established significance. It has also shown its significant influence on the clinical
outcome (notably BCSS) in older women receiving adjuvant endocrine therapy. Further studies are
required to investigate and compare the expression of LKB1 in and with the younger patients and
to delineate the precise role of LKB1 as a potential therapeutic target in breast cancer management.
Studies are also required to understand the detailed genetics of LKB1.
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Metastasis-free survival according to the expression of LKB1 in older women with early operable primary breast
cancer who received adjuvant endocrine therapy, Figure S2. (a) Metastases free survival in LKB1 positive early
operable primary breast cancer in older women: Ki67 positive versus Ki67 negative. (b) Metastasis-free survival
in LKB1 positive early operable primary breast cancer in older women: CK17 positive versus CK17 negative. (c)
Metastasis-free survival in LKB1 positive early operable primary breast cancer in older women: EGFR positive
versus EGFR negative.
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